Jennifer A. Woyach, MD, has been named the new director of the division of hematology at The Ohio State University ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

BeyondSpring (BYSI) has entered into definitive agreements to sell a portion of its Series A-1 Preferred Shares of SEED Therapeutics for gross ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune diseases, a continued appetite for next-generation obesity drugs and an increased ...

We recently published a list of 12 Stocks That Could Split in the Near Future. In this article, we are going to take a look ...

Lilly’s bid to acquire Scorpion was driven by the Scorpion ... including one involving another oncology biotech—that of the Johnson and Johnson acquiring Intracellular Therapies. Pharma and biotech ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...